Abbvie Inc
NYSE: ABBV
$175.17
-$3.33 (-1.9%)
Closing Price on January 10, 2025
ABBV Articles
A new report from Jefferies updates the firm's top global pharmaceutical stocks to buy, and these picks make sense for investors now.
Published:
The June 30 short interest data have been compared with the previous figures, and across the selected pharmaceutical stocks, short interest decreased.
Published:
A new report from UBS highlights three stocks that the firm likes best now. Not only do they all pay a solid dividend and have a good potential for growth, they all could help cushion a portfolio...
Published:
How much are big pharmaceutical companies really spending to get their drugs out there in the public eye?
Published:
The June 15 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
Published:
We screened the Jefferies Franchise Pick List for top stocks rated Buy with the highest upside to the Jefferies price targets.
Published:
The May 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest is down.
Published:
AT&T continued to reign as the most shorted stock trading on the New York Stock Exchange between the May 15 and May 29 settlement dates.
Published:
Credit Suisse has updated its autoimmune market model and it sees implications for all of the large cap U.S. pharmaceutical companies in its coverage.
Published:
Halozyme Therapeutics has announced a global collaboration and license agreement with AbbVie.
Published:
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. ThinkstockThe American Society of Clinical Oncology’s...
Published:
The short interest data has been released for the May 15 settlement date and for the selected pharmaceutical stocks, short interest is mixed.
Published:
Wednesday's top analyst upgrades, downgrades and initiations include Ambarella, eBay, Rite Aid, TiVo, Yahoo, Valero Energy and Virtu Financial.
Published:
With major mergers and acquisition deals happening, and a host of clinical trials that could offer some outstanding breakthrough drug treatments, the big pharmaceutical stocks have had their fair...
Published:
The April 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
Published:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.